Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME

1.50 CME
90 MINS
$0 FEE
SAVE
Rapid Reviews in Retina

Overview


Release Date
December 31, 2023

Expiration Date
December 31, 2024

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, , is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Activity Overview

Prominent eye care meetings, such as the AAO Annual Meeting, the EURETINA Congress, and the Retina Society Annual Scientific Meeting, are premier opportunities to learn about emerging data that has the potential to change the management of neovascular retinal disease. However, clinicians cannot attend all major conferences or retain all the highlights from meetings they do attend. This Rapid Reviews in Retina program provides concise discussions of recent data on advances in the management of nAMD and DME, as well as faculty discussions regarding how these data may shape patient care.

Target Audience

This educational activity is directed towards retina specialists and other ophthalmologists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize emerging evidence regarding the management of retinal diseases as presented at major medical conferences in 2023
  • Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of nAMD based on clinical presentation and goals of treatment
  • Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of DME based on clinical presentation and goals of treatment

Faculty

Diana Do Faculty Headshot
Diana Do, MD
Professor of Ophthalmology
Standford Medicine
Palo Alto, CA

Disclosures: Research: Regeneron, Boerhinger Ingelheim, Regenxbio, Lumithera. Consultant: Regeneron, Kodiak Sciences, Lumithera, Apellis Pharmaceuticals, Iveric, Boerhinger Ingelheim. Stockholder: Kodiak Sciences.

Eichenbaum Faculty Headshot
David A. Eichenbaum, MD
Director, Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Clearwater, FL

Disclosures: Grant/Research Support: 4DMT Molecular Therapeutics, Alexion, Allegenesis Biotherapeutics, Annexon, Aviceda Therapeutics, Bayer, EyePoint Pharmaceuticals, Gemini, Gyroscope Therapeutics, Ionis Pharmaceuticals, IVERIC bio, Janssen, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, ONL Therapeutics, Opthea, RecensMedical, Regeneron Pharmaceuticals, REGENXBIO,Unity. Consultant: Alimera Sciences, Allergan, Annexon, Apellis Pharmaceuticals, Bausch + Lomb, Coherus BioSciences, Crinetics Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, IVERIC bio, Kodiak Sciences, Ocular Therapeutix, Opthea, Outlook Therapeutics, RecensMedical, Regeneron Pharmaceuticals, REGENXBIO, ReVive, Samsara.

Garg Faculty Headshot
Sunir J. Garg, MD
Co-Director, Retina Research
Wills Eye Hospital
Philadelphia, PA

Disclosures: Consultant: Allergan, American Academy of Ophthalmology, Apellis, Bausch & Lomb, Boehringer lngelheim, Coherus, Genentech/Roche, Johnson & Johnson, Merck Manuals, Regeneron. Research: Adverum, Alexion, American Academy of Ophthalmology, Annexon, Apellis, Astellas, Avonelle-X, Boehringer lngelheim, Genentech, Gyroscope, lveric Bio, Jefferson, KCRN, Kodiak, Lineage Cell Therapeutics, MUST Network, NGM Bio, Ocugen, Ocuterra, Opthea, Regeneron, RegenxBio, Roche/Genentech.

Sivaprasad Faculty Headshot
Sobha Sivaprasad, DM, FRCOphth
Professor and Consultant Ophthalmologist
Moorfields Eye Hospital
London, UK

Disclosures: Research: AbbVie. Stockholder: Eyebiotech. Honoraria: Bayer, Roche, Boehringer Ingleheim, Novartis, Biogen, Amgen.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.